Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.26)
# 4,410
Out of 5,134 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $43.69 | +9.86% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $11.18 | +168.34% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $101.16 | -22.89% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $28.29 | +41.39% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.66 | +3,391.73% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $43.69
Upside: +9.86%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $11.18
Upside: +168.34%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $101.16
Upside: -22.89%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $28.29
Upside: +41.39%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.66
Upside: +3,391.73%